194 related articles for article (PubMed ID: 31993860)
1. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
[TBL] [Abstract][Full Text] [Related]
2. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
[TBL] [Abstract][Full Text] [Related]
3. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
5. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
6. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
8. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.
Bychkovsky BL; Agaoglu NB; Horton C; Zhou J; Yussuf A; Hemyari P; Richardson ME; Young C; LaDuca H; McGuinness DL; Scheib R; Garber JE; Rana HQ
JAMA Oncol; 2022 Nov; 8(11):1598-1606. PubMed ID: 36136322
[TBL] [Abstract][Full Text] [Related]
9. Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.
Sutcliffe EG; Stettner AR; Miller SA; Solomon SR; Marshall ML; Roberts ME; Susswein LR; Arvai KJ; Klein RT; Murphy PD; Hruska KS
Cancer Genet; 2020 Aug; 246-247():12-17. PubMed ID: 32805687
[TBL] [Abstract][Full Text] [Related]
10. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.
Hinić S; Cybulski C; Van der Post RS; Vos JR; Schuurs-Hoeijmakers J; Brugnoletti F; Koene S; Vreede L; van Zelst-Stams WAG; Kets CM; Haadsma M; Spruijt L; Wevers MR; Evans DG; Wimmer K; Schnaiter S; Volk AE; Möllring A; de Putter R; Soikkonen L; Kahre T; Tooming M; de Jong MM; Vaz F; Mensenkamp AR; Genuardi M; Lubinski J; Ligtenberg M; Hoogerbrugge N; de Voer RM
Genet Med; 2024 May; 26(5):101101. PubMed ID: 38362852
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Breast Cancer Risk Assessment for
Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
[TBL] [Abstract][Full Text] [Related]
12. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
13. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
15. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
16. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.
Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T
Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337
[TBL] [Abstract][Full Text] [Related]
17. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
18. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
19. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G
Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
